Clearmind Medicine (CMND) said Monday that a US patent application has been published by the US Patent and Trademark Office for its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, targeting binge behavior disorders.

The clinical-stage biotech company said this patent application stems from its ongoing collaboration with SciSparc (SPRC), and that this therapy targets multiple binge behaviors, including excessive alcohol consumption binge eating, smoking, compulsive shopping, and problematic sexual conduct.

Clearmind Medicine shares were up less than 1% in recent Monday premarket activity, while SciSparc's were up 23%.